Economy/Home · Economy

HLB Shares Fall to 39,950 Won, Slipping Below the 40,000-Won Level... Market Eyes Direction in Final Week of October

HLB (028300) showed weakness in the morning session on the 26th, dropping below the 40,000-won level. As the final trading week of October begins, market attention is focused on whether the stock can recover the 40,000-won range. As of 2 p.m. on the 26th, HLB is trading at 39,950 won, down 1,650 wo

Oseong Kwon
Staff Reporter
3 min read
HLB Shares Fall to 39,950 Won, Slipping Below the 40,000-Won Level... Market Eyes Direction in Final Week of October
CBC News

HLB (028300) showed weakness in the morning session on the 26th, dropping below the 40,000-won level. As the final trading week of October begins, market attention is focused on whether the stock can recover the 40,000-won range.

As of 2 p.m. on the 26th, HLB is trading at 39,950 won, down 1,650 won (-3.97%) from the previous trading day. HLB posted a decline in the high 3% range today, slightly falling below the 40,000-won level.

■ Opens with selling dominance... key points to watch this week

With a selling-dominant trend emerging from the start of the week, HLB's price movement this week is a key point to watch. Whether the stock can re-enter the 40,000-won range and narrow its decline is also worth monitoring.

■ Anticancer drug developer bio stock... volatility and supply-demand variables persist

HLB is a bio stock whose progress on anticancer drug development can influence investor sentiment. However, it cannot be assumed that such business-related developments will immediately translate into short-term stock price gains. The volatility characteristic of the biotech sector and overall market supply and demand conditions must also be considered.

Attention is on whether HLB can reclaim the 40,000-won level and shift the mood by the 30th, the final trading day of October, or whether the stock will see further correction.

■ HLB Pharmaceutical, HLB Life Science, and HLB Innovation also decline together

Meanwhile, group affiliates such as HLB Pharmaceutical, HLB Life Science, and HLB Innovation are also showing weakness at the same time.

[This article was written for the purpose of conveying market price information and does not constitute a recommendation to invest in any specific asset.]

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.